アルテプラーゼ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "アルテプラーゼ" in Japanese language version.

refsWebsite

Global rank Japanese rank

53nih.gov

4^th place

24^th place

28doi.org

2^nd place

6^th place

10web.archive.org

1^st place

3pmda.go.jp

6,690^th place

394^th place

2drugs.com

399^th place

1,603^rd place

2fda.gov

447^th place

1,043^rd place

2handle.net

102^nd place

78^th place

1europa.eu

68^th place

425^th place

1cadth.ca

low place

1acc.org

low place

acc.org

“Management of PE”. American College of Cardiology (January 2020). 28 November 2020時点のオリジナルよりアーカイブ。2020年10月30日閲覧。

cadth.ca

Marchand DK, Farrah K (9 July 2019). Thrombolytics for Acute Myocardial Infarction in a Pre-Hospital Setting: A Review of Comparative Safety and Guidelines (PDF). CADT (Report). 2019年10月20日時点のオリジナルよりアーカイブ (PDF)。2020年11月12日閲覧。

doi.org

“Management of occlusion and thrombosis associated with long-term indwelling central venous catheters”. Lancet 374 (9684): 159–69. (July 2009). doi:10.1016/S0140-6736(09)60220-8. PMC 2814365. PMID 19595350.
“2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines”. Circulation 127 (4): e362-425. (January 2013). doi:10.1161/CIR.0b013e3182742cf6. PMID 23247304.
“Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association”. Stroke 50 (12): e344–e418. (December 2019). doi:10.1161/STR.0000000000000211. PMID 31662037.
“2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association”. Stroke 49 (3): e46–e110. (March 2018). doi:10.1161/STR.0000000000000158. PMID 29367334.
Solomon, Caren G., ed (July 2020). “Acute Ischemic Stroke”. The New England Journal of Medicine 383 (3): 252–260. doi:10.1056/NEJMcp1917030. PMID 32668115.
“Mechanical Thrombectomy Outcomes With and Without Intravenous Thrombolysis in Stroke Patients: A Meta-Analysis”. Stroke 48 (9): 2450–2456. (September 2017). doi:10.1161/STROKEAHA.117.017320. PMID 28747462.
“Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association”. Stroke 47 (2): 581–641. (February 2016). doi:10.1161/STR.0000000000000086. PMID 26696642.
“Safety and Efficacy of Repeated Thrombolysis with Alteplase in Early Recurrent Ischemic Stroke: A Systematic Review”. Journal of Stroke and Cerebrovascular Diseases 28 (10): 104290. (October 2019). doi:10.1016/j.jstrokecerebrovasdis.2019.07.006. PMID 31371140.
“Pediatric Thrombolysis: A Practical Approach”. Frontiers in Pediatrics 5: 260. (December 2017). doi:10.3389/fped.2017.00260. PMC 5723643. PMID 29270396.
“Thrombolysis in pediatric stroke study”. Stroke 46 (3): 880–5. (March 2015). doi:10.1161/STROKEAHA.114.008210. PMC 4342311. PMID 25613306.
“Recombinant tissue plasminogen activators (rtPA): a review”. Clinical Pharmacology and Therapeutics 97 (3): 274–85. (2015-03). doi:10.1002/cpt.33. PMID 25670034.
“Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis”. Lancet 390 (10096): 747–759. (August 2017). doi:10.1016/s0140-6736(17)31441-1. PMID 28831992.
“Update on Thrombolytic Therapy in Acute Pulmonary Thromboembolism”. The Eurasian Journal of Medicine 51 (2): 186–190. (June 2019). doi:10.5152/eurasianjmed.2019.19291. PMC 6592452. PMID 31258361.
“Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review”. European Heart Journal 35 (12): 758–64. (March 2014). doi:10.1093/eurheartj/ehu029. PMID 24497337.
“Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis”. Thrombosis Research 133 (3): 357–63. (March 2014). doi:10.1016/j.thromres.2013.12.026. PMID 24412030.
“Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials”. Circulation 110 (6): 744–9. (August 2004). doi:10.1161/01.CIR.0000137826.09715.9C. PMID 15262836.
“Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report”. Chest 149 (2): 315–352. (February 2016). doi:10.1016/j.chest.2015.11.026. PMID 26867832.
“Thrombolytic therapy for central venous catheter occlusion”. Haematologica 97 (5): 641–50. (May 2012). doi:10.3324/haematol.2011.050492. PMC 3342964. PMID 22180420.
“Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review”. Pharmacotherapy 31 (10): 1031–40. (October 2011). doi:10.1592/phco.31.10.1031. PMID 21950645.
“Changing contraindications for t-PA in acute stroke: review of 20 years since NINDS”. Current Cardiology Reports 17 (10): 81. (October 2015). doi:10.1007/s11886-015-0633-5. PMID 26277361.
“Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials”. Lancet 384 (9958): 1929–35. (November 2014). doi:10.1016/S0140-6736(14)60584-5. PMC 4441266. PMID 25106063.
“The tissue-type plasminogen activator story”. Arteriosclerosis, Thrombosis, and Vascular Biology 29 (8): 1151–5. (August 2009). doi:10.1161/ATVBAHA.108.179655. PMID 19605778.
“Twenty-Year History of the Evolution of Stroke Thrombolysis With Intravenous Alteplase to Reduce Long-Term Disability”. Stroke 46 (8): 2341–6. (August 2015). doi:10.1161/STROKEAHA.114.007564. PMID 26152294.
“Tissue-type plasminogen activator: a historical perspective and personal account”. Journal of Thrombosis and Haemostasis 2 (4): 541–6. (April 2004). doi:10.1111/j.1538-7933.2004.00645.x. PMID 15102005.
“Factors delaying intravenous thrombolytic therapy in acute ischaemic stroke: a systematic review of the literature”. Journal of Neurology 268 (8): 2723–2734. (March 2020). doi:10.1007/s00415-020-09803-6. PMID 32206899.
“Presentation, Evaluation, Management, and Outcomes of Acute Stroke in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis”. Neuroepidemiology 51 (1–2): 104–112. (2018). doi:10.1159/000491442. PMC 6322558. PMID 30025394.
“Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis”. Trials 17 (1): 473. (September 2016). doi:10.1186/s13063-016-1595-7. PMC 5039798. PMID 27677444.
“Sex differences in IV thrombolysis treatment for acute ischemic stroke: A systematic review and meta-analysis”. Neurology 95 (1): e11–e22. (July 2020). doi:10.1212/wnl.0000000000009733. PMID 32522796.

drugs.com

“Alteplase Use During Pregnancy”. Drugs.com. 27 August 2020時点のオリジナルよりアーカイブ。12 November 2019閲覧。
“Alteplase Monograph for Professionals”. Drugs.com. 27 August 2020時点のオリジナルよりアーカイブ。11 November 2019閲覧。

europa.eu

ema.europa.eu

“Actilyse”. European Medicines Agency. 17 November 2020時点のオリジナルよりアーカイブ。14 November 2020閲覧。

fda.gov

accessdata.fda.gov

“HIGHLIGHTS OF PRESCRIBING INFORMATION - ACTIVASE (alteplase) for injection, for intravenous use”. 2021年12月20日閲覧。
“Activase: FDA-Approved Drugs”. U.S. Food and Drug Administration (FDA). 27 August 2020時点のオリジナルよりアーカイブ。4 January 2020閲覧。

handle.net

hdl.handle.net

World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. (2019). hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO
Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. (2019). hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO

nih.gov

pubmed.ncbi.nlm.nih.gov

“Management of occlusion and thrombosis associated with long-term indwelling central venous catheters”. Lancet 374 (9684): 159–69. (July 2009). doi:10.1016/S0140-6736(09)60220-8. PMC 2814365. PMID 19595350.
“Tissue Plasminogen Activator”. StatPearls. Treasure Island (FL): StatPearls Publishing. (April 2020). PMID 29939694. オリジナルの29 January 2021時点におけるアーカイブ。 2020年11月10日閲覧。
“2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines”. Circulation 127 (4): e362-425. (January 2013). doi:10.1161/CIR.0b013e3182742cf6. PMID 23247304.
“Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association”. Stroke 50 (12): e344–e418. (December 2019). doi:10.1161/STR.0000000000000211. PMID 31662037.
“2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association”. Stroke 49 (3): e46–e110. (March 2018). doi:10.1161/STR.0000000000000158. PMID 29367334.
“Alteplase”. StatPearls. Treasure Island (FL): StatPearls Publishing. (2020). PMID 29763152. オリジナルの29 January 2021時点におけるアーカイブ。 2020年10月30日閲覧。
Solomon, Caren G., ed (July 2020). “Acute Ischemic Stroke”. The New England Journal of Medicine 383 (3): 252–260. doi:10.1056/NEJMcp1917030. PMID 32668115.
“Mechanical Thrombectomy Outcomes With and Without Intravenous Thrombolysis in Stroke Patients: A Meta-Analysis”. Stroke 48 (9): 2450–2456. (September 2017). doi:10.1161/STROKEAHA.117.017320. PMID 28747462.
“Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association”. Stroke 47 (2): 581–641. (February 2016). doi:10.1161/STR.0000000000000086. PMID 26696642.
“Safety and Efficacy of Repeated Thrombolysis with Alteplase in Early Recurrent Ischemic Stroke: A Systematic Review”. Journal of Stroke and Cerebrovascular Diseases 28 (10): 104290. (October 2019). doi:10.1016/j.jstrokecerebrovasdis.2019.07.006. PMID 31371140.
“Pediatric Thrombolysis: A Practical Approach”. Frontiers in Pediatrics 5: 260. (December 2017). doi:10.3389/fped.2017.00260. PMC 5723643. PMID 29270396.
“Thrombolysis in pediatric stroke study”. Stroke 46 (3): 880–5. (March 2015). doi:10.1161/STROKEAHA.114.008210. PMC 4342311. PMID 25613306.
“Recombinant tissue plasminogen activators (rtPA): a review”. Clinical Pharmacology and Therapeutics 97 (3): 274–85. (2015-03). doi:10.1002/cpt.33. PMID 25670034.
“Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis”. Lancet 390 (10096): 747–759. (August 2017). doi:10.1016/s0140-6736(17)31441-1. PMID 28831992.
“Update on Thrombolytic Therapy in Acute Pulmonary Thromboembolism”. The Eurasian Journal of Medicine 51 (2): 186–190. (June 2019). doi:10.5152/eurasianjmed.2019.19291. PMC 6592452. PMID 31258361.
“Systemic Thrombolysis for Pulmonary Embolism: A Review”. P & T 41 (12): 770–775. (December 2016). PMC 5132419. PMID 27990080.
“Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review”. European Heart Journal 35 (12): 758–64. (March 2014). doi:10.1093/eurheartj/ehu029. PMID 24497337.
“Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis”. Thrombosis Research 133 (3): 357–63. (March 2014). doi:10.1016/j.thromres.2013.12.026. PMID 24412030.
“Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials”. Circulation 110 (6): 744–9. (August 2004). doi:10.1161/01.CIR.0000137826.09715.9C. PMID 15262836.
“Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report”. Chest 149 (2): 315–352. (February 2016). doi:10.1016/j.chest.2015.11.026. PMID 26867832.
“Thrombolytic therapy for central venous catheter occlusion”. Haematologica 97 (5): 641–50. (May 2012). doi:10.3324/haematol.2011.050492. PMC 3342964. PMID 22180420.
“Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review”. Pharmacotherapy 31 (10): 1031–40. (October 2011). doi:10.1592/phco.31.10.1031. PMID 21950645.
“Changing contraindications for t-PA in acute stroke: review of 20 years since NINDS”. Current Cardiology Reports 17 (10): 81. (October 2015). doi:10.1007/s11886-015-0633-5. PMID 26277361.
“Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials”. Lancet 384 (9958): 1929–35. (November 2014). doi:10.1016/S0140-6736(14)60584-5. PMC 4441266. PMID 25106063.
“The tissue-type plasminogen activator story”. Arteriosclerosis, Thrombosis, and Vascular Biology 29 (8): 1151–5. (August 2009). doi:10.1161/ATVBAHA.108.179655. PMID 19605778.
“Twenty-Year History of the Evolution of Stroke Thrombolysis With Intravenous Alteplase to Reduce Long-Term Disability”. Stroke 46 (8): 2341–6. (August 2015). doi:10.1161/STROKEAHA.114.007564. PMID 26152294.
“Tissue-type plasminogen activator: a historical perspective and personal account”. Journal of Thrombosis and Haemostasis 2 (4): 541–6. (April 2004). doi:10.1111/j.1538-7933.2004.00645.x. PMID 15102005.
“Factors delaying intravenous thrombolytic therapy in acute ischaemic stroke: a systematic review of the literature”. Journal of Neurology 268 (8): 2723–2734. (March 2020). doi:10.1007/s00415-020-09803-6. PMID 32206899.
“Presentation, Evaluation, Management, and Outcomes of Acute Stroke in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis”. Neuroepidemiology 51 (1–2): 104–112. (2018). doi:10.1159/000491442. PMC 6322558. PMID 30025394.
“Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis”. Trials 17 (1): 473. (September 2016). doi:10.1186/s13063-016-1595-7. PMC 5039798. PMID 27677444.
“Sex differences in IV thrombolysis treatment for acute ischemic stroke: A systematic review and meta-analysis”. Neurology 95 (1): e11–e22. (July 2020). doi:10.1212/wnl.0000000000009733. PMID 32522796.

ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

“Activase- alteplase kit”. DailyMed (5 December 2018). 11 January 2017時点のオリジナルよりアーカイブ。4 January 2020閲覧。
“Cathflo Activase- alteplase injection, powder, lyophilized, for solution”. DailyMed (6 September 2019). 29 January 2021時点のオリジナルよりアーカイブ。14 November 2020閲覧。

pmda.go.jp

info.pmda.go.jp

“アクチバシン注600万／アクチバシン注1200万／アクチバシン注2400万添付文書”. www.info.pmda.go.jp. 2021年12月20日閲覧。
“グルトパ注600万／グルトパ注1200万／グルトパ注2400万添付文書”. www.info.pmda.go.jp. 2021年12月20日閲覧。
“グルトパ注600万／グルトパ注1200万／グルトパ注2400万インタビューフォーム”. www.info.pmda.go.jp. 2021年12月20日閲覧。

web.archive.org

“Actilyse”. European Medicines Agency. 17 November 2020時点のオリジナルよりアーカイブ。14 November 2020閲覧。
“Activase- alteplase kit”. DailyMed (5 December 2018). 11 January 2017時点のオリジナルよりアーカイブ。4 January 2020閲覧。
“Cathflo Activase- alteplase injection, powder, lyophilized, for solution”. DailyMed (6 September 2019). 29 January 2021時点のオリジナルよりアーカイブ。14 November 2020閲覧。
“Alteplase Use During Pregnancy”. Drugs.com. 27 August 2020時点のオリジナルよりアーカイブ。12 November 2019閲覧。
“Alteplase Monograph for Professionals”. Drugs.com. 27 August 2020時点のオリジナルよりアーカイブ。11 November 2019閲覧。
“Tissue Plasminogen Activator”. StatPearls. Treasure Island (FL): StatPearls Publishing. (April 2020). PMID 29939694. オリジナルの29 January 2021時点におけるアーカイブ。 2020年11月10日閲覧。
“Alteplase”. StatPearls. Treasure Island (FL): StatPearls Publishing. (2020). PMID 29763152. オリジナルの29 January 2021時点におけるアーカイブ。 2020年10月30日閲覧。
Marchand DK, Farrah K (9 July 2019). Thrombolytics for Acute Myocardial Infarction in a Pre-Hospital Setting: A Review of Comparative Safety and Guidelines (PDF). CADT (Report). 2019年10月20日時点のオリジナルよりアーカイブ (PDF)。2020年11月12日閲覧。
“Management of PE”. American College of Cardiology (January 2020). 28 November 2020時点のオリジナルよりアーカイブ。2020年10月30日閲覧。
“Activase: FDA-Approved Drugs”. U.S. Food and Drug Administration (FDA). 27 August 2020時点のオリジナルよりアーカイブ。4 January 2020閲覧。